

RARE DISEASES
&
INDIANA ONCOLOGY NURSING
SOCIETY
SYMPOSIUMS
2024 PROGRAM

Sponsored by:



Achieving tomorrow's outcomes through education today.™

RARE DISEASES SYMPOSIUM

Agenda

Meeting Room - Cabinet/Caucus

Chair: Ruemu E. Birhiray, MD and Co-Chair: Sumeet Bhatia, MD

7:50AM - 7:55AM	Introduction and Welcome: What We Do: Treatment of Rare Diseases in Community Oncology Practices Ruemu Birhiray, MD, President/CEO, Indy Hematology Education, Inc.
7:55AM - 8:15AM	How we diagnose and treat Systemic Mastocytosis Tsewang Tashi, MD, Associate Professor of Medicine, Huntsman Cancer Institute
8:15AM - 8:35AM	Practical Strategies for Managing Leukemias in Community Oncology: Managing the Patient Who is Not Eligible for Intensive Chemotherapy, and Small Molecule Targeted Therapy in Community Oncology Practices Michael Thirman, MD, Associate Professor of Medicine, University of Chicago
8:35AM - 8:50AM	BREAK
8:50AM - 9:10AM	Heralding The Era of Curable Therapy for Acute Lymphoblastic Leukemia: Monoclonal Antibodies and Targeted Therapy in Community Oncology Mark Robert Litzow, MD, Professor of Medicine, Mayo Clinic School of Graduate Medical Education
9:10AM - 9:35AM	How We Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Anthony Stein, Professor, City of Hope
9:35AM - 10:00AM	Contemporary Approaches to the Management of T-Cell Lymphomas/Leukemias Francine Foss, MD, Professor of Medicine, Smilow Comprehensive Cancer Center, Yale School of Medicine
10:00AM - 10:20AM	Acute Leukemia and Lymphoma Panel Discussion
10:20AM - 10:35AM	BREAK
10:35AM - 11:00AM	Anxiety Inducing Hematologic Disorders: Managing the Patient with Cold Agglutinin Disease, Thrombotic Thrombocytopenic Purpura and Paroxysmal Nocturnal Hemoglobinuria Catherine Broome, MD, Professor of Medicine, MedStar Georgetown University Hospital
11:00AM - 11:25AM	Current Approaches to the Management of Hemophagocytic Lymphohistiocytosis: Recognition, Diagnosis and Treatment Lorisa Broglie, MD, MS, Associate Professor of Pediatrics, Medical College of Wisconsin
11:25AM - 11:40AM	BREAK
11:40AM - 12:05AM	Recognizing and Treatment of Porphyrrias: Evaluation and Management Herbert Bonkovsky, MD, Professor of Medicine and Molecular Medicine & Translational Science, Wake Forest University School of Medicine
12:05AM - 12:30PM	Approaches and Treatment of Rare Plasma Cell Dyscrasias: Monoclonal Gammopathy of Renal Significance, POEMS Syndrome, Castleman Disease and Amyloidosis Angela Dispenzieri, MD, Professor of Medicine, Mayo Clinic
12:30PM - 12:50PM	Q/A and Panel Discussion
12:50PM - 1:05PM	BREAK
1:05PM - 2:05PM	LUNCH/Product Theater Chamber/Council
2:05PM - 2:25PM	Immunotherapy and T-Cell Directed Approaches to the Management of Small Cell Lung Cancer Kai He, MD, PhD, Associate Professor with Tenure, The Ohio State University
2:25PM - 2:50PM	Understanding Molecular Pathology and Targeting the Bulls Eye in Cancer Therapy: Targeted Therapy for Lung Cancer: Approaches to the Management of Patients with DRIVER Mutations Vivek Subbiah, Sarah Cannon Cancer institute
2:50PM - 3:15PM	“The No Name Cancer”: When All That Matters is Targeting the Tumor – Tumor Agnostic Therapy in Cancer Management Razelle Kurzrock, MD, Professor of Medicine, Associate Director, Clinical Research, Medical College of Wisconsin
3:15PM - 3:25PM	Q/A and Panel Discussion
3:25PM - 3:30PM	Adjourn Ruemu Birhiray, MD, President/CEO, Indy Hematology Education, Inc.

3:30PM - 4:30PM	Meet the Professor and Reception	Capitol 1&2 Foyer
-----------------	----------------------------------	-------------------

INDIANA ONCOLOGY NURSING SOCIETY SYMPOSIUM

Agenda

Meeting Room - Capitol 1

8:00AM - 8:05AM	Welcome Ruemu Birhiray, MD and Susan Ambruso, MS, FNP
8:05AM - 8:50AM	Oncologic Emergencies: Structural & Metabolic: A Nursing Perspective Alex Thullen, MSN, RN, AGCNS-BC, BMTCN, Clinical Nurse Specialist, Indiana University Health
8:50AM - 9:20AM	Navigating the Metastatic Patient Cassie Osborne, MSN, RN, Oncology Nurse Navigator, Community Health Network
9:20AM - 9:35AM	BREAK
9:35AM - 10:05AM	Love and Death: Conversations Before the Crises Joy Howard, DNP, RN, AGCNS-BC, ACHPN, Palliative Care Advanced Practice Nurse, Hancock Health
9:40AM - 10:50AM	Functional Medicine: What are Patients Being Told? Mary Allen, MSN, PMGT, AOCNS, ACNS-BC, Clinical Nurse Specialist, Indiana University Health
10:35AM - 10:50AM	Q/A
10:50AM - 11:05AM	BREAK
11:05AM - 11:35AM	Two Sides of the Coin of Oncology Nursing: Digging Deeper and Knowing When to Call for Help When Managing Patient's Receiving Bispecific Antibodies Elizabeth Romano, MSN, AGNP, Nurse Practitioner, Hematology Oncology of Indiana
11:35AM - 12:05PM	AYA Patients: What Are We Missing? Sarah Cook, Clinical Nurse Specialist, Parkview Health
12:05PM - 12:35PM	Save Our Souls: Art Therapy for the Cancer Patient Meaghan Wiggins, MA, LMHCA, Art Therapist, Clinical Hospital Coordinator, Cancer Support Community
12:35PM - 12:50PM	Q/A
12:50PM - 1:05PM	BREAK
1:05PM - 2:05PM	LUNCH/Product Theaters Chamber/Council
2:05PM - 2:20PM	BREAK
2:20PM - 2:50PM	Precision Medicine: A Case-Based Approach Christopher Fausel, PharmD, Director of Pharmacy, Precision Genomics, Indiana University Simon Comprehensive Cancer Center
2:50PM - 3:15PM	The Ongoing Evolution of Cancer Drug Therapy: What Will Impact Your Practice Today? Rowena Schwartz, PharmD, BCOP, FHOPA, Professor of Pharmacy Practice, University of Cincinnati
3:15PM - 3:20PM	Q/A
3:20PM - 3:30PM	Adjourn Susan Ambruso, MS, FNP, President, CIONS
3:30PM - 4:30PM	Meet the Professor and Reception Capitol 1&2 Foyer

GENERAL INFORMATION

Registration Desk – 7:15 a.m. – 2:30 p.m.

Capitol 1&2 Foyer

Exhibit Displays – 7:15 a.m. – 2:30 p.m.

Capitol 2

Round Robins – 8:00 a.m. – 3:30 p.m.

Cameral

Geron Product Theater – 1:05 p.m. – 2:05 p.m.

Chamber/Council

Complimentary WIFI during Symposium.

Log-on Network: IndyHematology Password: IndyHematology

CONTINUING EDUCATION INFORMATION

Title – IHE Oncology Nursing Society Symposium

Needs – Oncology Nurses need an update on the therapies that are available for their patients and how they can support cancer patients who are being treated with these new treatment options.

Learning Objectives (ACCME, ANCC, ACPE) – Upon completion of this activity, the participant should be able to:

1. Discuss the new therapies available to treat cancer patients and know how to support their patients who are on these new therapies.
2. Review best practices in supporting patients with oncologic toxicities and emergencies.
3. Discuss how to support cancer patients during the implementation of precision medicine and genomic tests in clinical practice.
4. Effectively navigate difficult conversations with their cancer patients.
5. Review strategies to avoid or manage burnout while supporting cancer patients.

SUCCESSFUL COMPLETION FOR ALL PARTICIPANTS – In order to receive CE, all participants must attend the entire Symposium from 8:00 am – 3:30 pm. AND complete a Post-Evaluation.

Physician Accreditation Statement – This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Indy Hematology Education, Inc. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement – Purdue University College of Pharmacy designates this live activity for a maximum of 5.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Pharmacists Accreditation Statement – Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/ equal opportunity institution. Universal Activity Number (UAN): 0018-9999-24-017-L01-P Contact Hours 5.5 (.55 CEUs)

Nurses Accreditation Statement – Purdue University Continuing Nursing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This live program is approved for 5.5 contact hours.

Faculty and Disclosure / Conflict of Interest Policy – To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships occurring within the past 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.

Disclosures will be provided prior to the start of the activity.

All relevant conflicts of interest will have been mitigated prior to the start of the activity.

PRESENTERS:

None of the planners, reviewers, Indy Hematology Education, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.

Questions regarding CE Credit should be submitted to Pharmacy-CECR@purdue.edu.

LEARNING OBJECTIVES

At the completion of this activity, participants should be able to:

1. Discuss new emerging Hematology Therapies in general and for Chronic Myeloid Leukemia, Acute Promyelocytic and Myeloid Leukemia, and Myeloproliferative Neoplasms.
2. Evaluate Molecular diagnosis, targeted therapies, and resistance mechanisms of Waldenström's Macroglobulinemia to assist in disease recognition.
3. Discuss the advancement of immune check point inhibitors within Hematologic Malignancies and updated treatment paradigms presented at the American Society of Hematology meeting in San Diego, CA in December 2018.
4. Recommend new regimens for Hematopoietic Stem Cell Transplantation and identification of Transplant Candidates.
5. Review the advancement in Benign Hematology research.

6. Review new treatment regimens in Follicular Lymphoma.

Title – IHE Rare Diseases Symposium

Needs – Oncology HCP’s need best practices to treat and support patients with rare cancers.

Learning Objectives (ACCME, MOC, ANCC, ACPE) – Upon completion of this activity, the participant should be able to:

1. Discuss strategies for recognizing, diagnosing and treating rare cancers.
2. Implement strategies to manage patients with rare cancers.
3. Apply best practices to support patients with rare cancers.
4. Effectively leverage the newest treatment options or clinical trial opportunities for patients with rare cancers.
5. Implement strategies to leverage and communicate effectively with the multidisciplinary healthcare team for patients with rare cancers.

SUCCESSFUL COMPLETION FOR ALL PARTICIPANTS – In order to receive CE, all participants must attend the entire Symposium from 7:55 am – 3:30 pm. AND complete a Post-Evaluation.

Physician Accreditation Statement – This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Indy Hematology Education, Inc. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement – Purdue University College of Pharmacy designates this live activity for a maximum of 5.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Part 2 – Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.



Pharmacists Accreditation Statement – Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/ equal opportunity institution. Universal Activity Number (UAN): 0018-9999-24-016-L01-P Contact Hours 5.5 (.55 CEUs)

Nurses Accreditation Statement – Purdue University Continuing Nursing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This live program is approved for 5.5 contact hours.

Faculty and Disclosure / Conflict of Interest Policy – To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships occurring within the past 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.

Disclosures will be provided prior to the start of the activity.

All relevant conflicts of interest will have been mitigated prior to the start of the activity.

PRESENTERS:

None of the planners, reviewers, Indy Hematology Education, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.

Questions regarding CE Credit should be submitted to Pharmacy-CECR@purdue.edu.

SUPPORTERS

Sponsored by



Product Theater



Gold Level



Bronze Level



EXHIBITOR LISTING

AbbVie
Acrotech Biopharma
ADC Therapeutics
Agios
Alexion
Amgen
Apellis Pharmaceuticals
AstraZeneca
BeiGene
BioPlus Specialty Pharmacy
Blueprint Medicines
Bristol Myers Squibb
Daiichi Sankyo, Inc.
Exelixis
Genentech
Genmab
Geron Corporation
Guardant Health
Incyte
Jazz Pharmaceuticals
Kyowa Kirin, Inc.
Menarini Stemline
Merck
Novartis
Novartis Oncology
Novartis Pharmaceuticals
Novo Nordisk
Omeros Corp.
Pfizer, Inc.
Pharmacosmos Therapeutics
Recordati Rare Disease
Rigel Pharmaceuticals
Sanofi
Secura Bio
Servier Pharmaceuticals
Sun Pharmaceutical Industries, Inc.
Syndax Pharmaceuticals, Inc.

SAVE THE DATE!

2025 Indy Hematology Review • Saturday, March 8, 2025 • Westin Indianapolis

Contact Indy Hematology Education:

email: Indyhr@conventionmanagers.com or
visit: <http://www.indyhematologyreview.com> or
call: 317-841-7171 for assistance